Domestic companies challenging Vesicare’s substance patent
On the 9th, Astellas Korea announced it filed a patent infringement prohibition suit over Vesicare jointly with its headquarters against CorePharm Bio to the Seoul Central District Court
Since no foreign pharmaceutical company has revealed the fact of filing a patent infringement suit to the pr...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
